#1stryker Welcome 2021 Analyst Day 2021 Analyst Day 1#2Analyst Day 2021 Preston Wells Vice President, Investor Relations stryker 2021 Analyst Day 2#32021 Agenda Overview Financial outlook Cost Transformation for Growth update Orthopaedics and Spine Spotlight: Trauma & Extremities MedSurg and Neurotechnology Spotlight: ASC panel Investor Q&A Product Fair: Safety and outcomes Analyst Day stryker Kevin Lobo, Chair and Chief Executive Officer Glenn Boehnlein, Vice President, Chief Financial Officer Viju Menon, Group President, Global Quality and Operations Spencer Stiles, Group President, Orthopaedics and Spine Mike Panos, President, Trauma & Extremities Andy Pierce, Group President, MedSurg and Neurotechnology Nate Miersma, Senior Director, Ambulatory Surgery Center Stryker leadership team Dylan Crotty, President, Instruments 2021 Analyst Day 3#4Disclaimer stryker Forward-looking statements This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: the impact of the COVID-19 pandemic and related policies and actions by governments or third parties; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright; the effects of the Wright acquisition on the parties' relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements. Non-GAAP financial measures Organic sales growth, adjusted operating income margin, adjusted net earnings per diluted share, free cash flow and free cash flow conversion as shown in this presentation are non-GAAP financial measures. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, operating income margin, net earnings per diluted share and cash provided by operating activities, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures, provide a more complete understanding of our business. We are unable to present a quantitative reconciliation of our expected sales growth, operating income margin, net earnings per diluted share and cash provided by operating activities to expected organic sales growth, adjusted operating income margin, adjusted net earnings per diluted share, free cash flow and free cash flow conversion. Refer to the Appendix attached to this presentation for the definition of these non-GAAP financial measures and for the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures. 2021 Analyst Day 4#5Overview Kevin Lobo Chair and Chief Executive Officer stryker 2021 Analyst Day 5#6Mission Together with our customers, we are driven to make healthcare better. Values Integrity We do what's right Accountability We do what we say stryker People We grow talent Performance We deliver 2021 Analyst Day 6#7Copyright © 2021 Stryker NA stryker I'm stor stryker stryker Celebrating 80 years of making healthcare better 2021 Analyst Day 7#82021 Our people and culture keep us growing stryk Analyst Day anykere stryker Together with our customers, we are driven to make healthcare better. stryker #More Than Just Jaf O Grad nhan po stryker World's Best Workplaces Great Place to Work 2021 2021 Analyst Day 8#9Leadership team Kevin A. Lobo Chair and CEO Glenn S. Boehnlein Vice President, Chief Financial Officer Robert S. Fletcher Vice President, Chief Legal Officer Viju S. Menon Group President, Global Quality and Operations Yin C. Becker Vice President, Chief Corporate Affairs Officer Special thank you! stryker Timothy J. Scannell President and Chief Operating Officer J. Andrew (Andy) Pierce Group President, MedSurg and Neurotechnology Spencer S. Stiles Group President, Orthopaedics and Spine. M. Kathryn (Katy) Fink Vice President, Chief Human Resources Officer 2021 Analyst Day 9#10Corporate Responsibility objective Creating a better, healthier world Stronger people We are committed to serving our communities and creating a healthy, diverse, equitable and inclusive workplace where employees thrive Advance a culture of inclusion, engagement and belonging Strengthen the diversity of our workforce and measure progress Healthier planet We are committed to reducing our environmental impact on the world through responsible, sustainable operations CO₂ ↓↓↓ Our key commitments Realize 20% reduction in carbon emissions for all Stryker facilities 2019- 2024*1 Become Carbon neutral for all Stryker facilities by 2030*¹ *Scopes 1 and 2¹ Good business We are committed to helping customers improve patient outcomes and growing responsibly by pursuing quality and integrity in everything we do 88 Increase supply chain transparency and supplier diversity Establish formal accountability to the Board of Directors for Corporate Responsibility 2021 Analyst Day 10